ATE452185T1 - Dimethylarginin-dimethylaminohydrolasen - Google Patents

Dimethylarginin-dimethylaminohydrolasen

Info

Publication number
ATE452185T1
ATE452185T1 AT00901731T AT00901731T ATE452185T1 AT E452185 T1 ATE452185 T1 AT E452185T1 AT 00901731 T AT00901731 T AT 00901731T AT 00901731 T AT00901731 T AT 00901731T AT E452185 T1 ATE452185 T1 AT E452185T1
Authority
AT
Austria
Prior art keywords
dimethylarginine
dimethylaminohydrolases
ddahs
activators
genes
Prior art date
Application number
AT00901731T
Other languages
English (en)
Inventor
Patrick John Thompson Vallance
James Mitchell Leiper
Guy St John Whitley
Ian George Charles
Original Assignee
Univ London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9901705.5A external-priority patent/GB9901705D0/en
Priority claimed from GBGB9913066.8A external-priority patent/GB9913066D0/en
Application filed by Univ London filed Critical Univ London
Application granted granted Critical
Publication of ATE452185T1 publication Critical patent/ATE452185T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT00901731T 1999-01-26 2000-01-26 Dimethylarginin-dimethylaminohydrolasen ATE452185T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9901705.5A GB9901705D0 (en) 1999-01-26 1999-01-26 Screen method
GBGB9913066.8A GB9913066D0 (en) 1999-06-04 1999-06-04 Screen method
PCT/GB2000/000226 WO2000044888A2 (en) 1999-01-26 2000-01-26 Dimethylarginine dimethylaminohydrolases

Publications (1)

Publication Number Publication Date
ATE452185T1 true ATE452185T1 (de) 2010-01-15

Family

ID=26315038

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00901731T ATE452185T1 (de) 1999-01-26 2000-01-26 Dimethylarginin-dimethylaminohydrolasen

Country Status (8)

Country Link
US (1) US20050153315A1 (de)
EP (1) EP1144605B1 (de)
JP (1) JP2002535001A (de)
AT (1) ATE452185T1 (de)
AU (1) AU2303800A (de)
DE (1) DE60043533D1 (de)
ES (1) ES2336416T3 (de)
WO (1) WO2000044888A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020449D0 (en) * 2000-08-18 2000-10-11 Univ London Crystal structure
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
US9096663B2 (en) 2001-02-15 2015-08-04 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins and mutants thereof
US7556810B2 (en) 2005-07-19 2009-07-07 The Board Of Trustees Of The University Of Ilinois Compositions and methods to control angiogenesis with cupredoxins
US20040214264A1 (en) * 2002-04-19 2004-10-28 Veli-Pekka Valkonen Nucleic acid molecule encoding a variant DDAH 1 protein and uses thereof
GB0211295D0 (en) * 2002-05-16 2002-06-26 Univ London Treatment of pain
GB0211297D0 (en) * 2002-05-16 2002-06-26 Univ London Pain treatment
CN1656123A (zh) * 2002-05-31 2005-08-17 尤尼特尔药品公司 用于评估心血管疾病危险性的蛋白和方法
US9434770B2 (en) 2004-10-07 2016-09-06 Tapas K Das Gupta Modified cupredoxin derived peptides
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
UA97466C2 (ru) 2004-10-07 2012-02-27 Ананда Чакрабарти Транспортирующие соединения - производные купредоксина и способы их применения
US8232244B2 (en) 2007-02-08 2012-07-31 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
US9968685B2 (en) 2004-10-07 2018-05-15 Brad N. Taylor Methods to treat cancer with cupredoxins
US9598470B2 (en) 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
EP1904642A4 (de) 2005-07-19 2008-11-26 Univ Illinois Transportmittel zur überquerung der blut-hirn-schranke und zum eindringen in gehirnkrebszellen sowie verwendungsverfahren dafür
SG174136A1 (en) * 2009-02-20 2011-10-28 Cdg Therapeutics Inc Compositions and methods to prevent and/or treat cancer with pa -card
US8486179B2 (en) * 2009-10-29 2013-07-16 Georgia Tech Research Corporation Method for producing carbon molecular sieve membranes in controlled atmospheres
US20120315281A1 (en) * 2011-05-13 2012-12-13 The Penn State Research Foundation Treatment of renal injury
WO2019028040A1 (en) * 2017-07-31 2019-02-07 Vasculonics Llc MODIFIED DDAH POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCEMENT FRAGMENT WITH ENHANCED PHARMACOLOGY AND USES THEREOF
CA3154382A1 (en) 2019-09-13 2021-03-18 The Trustees Of Indiana University Devices and methods for modulating adma in blood

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0965876A (ja) * 1995-08-31 1997-03-11 Green Cross Corp:The 動物細胞の振盪培養方法および培養容器
EP0929681B1 (de) * 1996-08-20 2006-09-13 Novartis AG Rifamycin biosynthese genkluster
US6607879B1 (en) * 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
DE19820190A1 (de) * 1998-04-28 1999-11-04 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Pankreas-Tumor
JP2003528567A (ja) * 1998-11-12 2003-09-30 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトヒドロラーゼタンパク質

Also Published As

Publication number Publication date
JP2002535001A (ja) 2002-10-22
EP1144605A2 (de) 2001-10-17
WO2000044888A2 (en) 2000-08-03
EP1144605A3 (de) 2002-03-27
AU2303800A (en) 2000-08-18
WO2000044888A3 (en) 2001-12-13
ES2336416T3 (es) 2010-04-13
US20050153315A1 (en) 2005-07-14
EP1144605B1 (de) 2009-12-16
DE60043533D1 (de) 2010-01-28

Similar Documents

Publication Publication Date Title
DE60043533D1 (de)
BR9909248A (pt) Inibidores de enzima
DE69936720D1 (de) Menschliche cd45+ und/oder fibroblasten+ mesenchymale stammzellen
NO20052928L (no) Nye kjemiske forbindelser
NO20051788L (no) Hydantoinderivater og deres anvendelse som TACE-inhibitorer
NO20050497L (no) Anvendelse av CETP inhibitorer og eventuelt HMG COA reduserbare inhibitorer og/eller antihypertensiva
NO20035086L (no) Karboksylsyresubstituerte oxazolderivater for anvendelse som PPAR-alfa og gamma-aktivatorer i behandling av diabetes
NO20033742L (no) Omega-aminoalkylamider av R-2-arylpropionsyrer som inhibitorer av polymofonukle¶re og mononukle¶re cellers kjemotakse
TR199802441A2 (xx) Kanda a��r� �rik asit bulunmas�n�n tedavisi ve �nlenmesi i�in y�ntem ve terkip.
DK0755249T3 (da) Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
NO20071019L (no) Quinazolinderivater og deres anvendelse ved behandling av trombocytemi
DE60214542D1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
EP1191941A4 (de) Methode der prophylaxe und/oder behandlung von erkrankungen
MY117526A (en) N-(3-benzofuranyl)urea-derivatives
HUS1000019I1 (hu) Karbonsav-tartalmú szerek és növénytermesztésben való alkalmazásuk
DE69931055D1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken
NO971444D0 (no) Inhibitor av stamcelle-proliferasjon og anvendelser derav
DE50308707D1 (de) Abbau und modifizierung von silicaten und siliconen durch silicase und verwendung des reversiblen enzyms
ATE446077T1 (de) Vektoren mit beiden isoformen von beta- hexosaminidase
NO20020130L (no) Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksis
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
EP1572901A4 (de) Transponierbare elemente in reis und verwendungsverfahren
NO20054670L (no) Behandling av intestinale tilstander med N-2,3,3-tetrametylbisyklo[2.2.1]-heptan-2-amid
JOP20240149A1 (ar) مثبطات bcl-2 (الخلية ب لمفومة 2)
SG155901A1 (en) Enzyme inhibitors and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties